Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Open accessAbstract
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The classification of GLP-1 RAs as short- or long-acting is closely linked to dosing frequency and differences in the degree of delayed gastric emptying.
“This classification is closely linked to dosing frequency and differences in the degree of delayed gastric emptying [9].”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369 · see citing works
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · see citing works
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834 · see citing works
Basevi, V., Mario, S. D., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,058 · see citing works
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167 · see citing works
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · see citing works
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479 · see citing works
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · see citing works
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · see citing works
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209 · see citing works
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetes Care · doi:10.2337/dc06-9912 · Cited by 1,195 · see citing works
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · see citing works
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · see citing works
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · see citing works
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · see citing works
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · see citing works
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · see citing works
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · see citing works
Aschner, P. J., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams‐Herman, D., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 878 · see citing works
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M.-B., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diabetes.44.9.1126 · Cited by 878 · see citing works
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · see citing works
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · see citing works
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · see citing works
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · see citing works
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835 · see citing works
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R. A., & Schmiegel, W. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 822 · see citing works
Marre, M., Shaw, J. E., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M. D., Thi, T. D. L., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 814 · see citing works
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795 · see citing works
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790 · see citing works
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · see citing works
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · see citing works
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 1× · see citing works
“Long-term effects include stimulation of insulin synthesis [4], an increase in b-cell proliferation and a reduction in apoptosis [5].”
BackgroundGlucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
Bose, A. K., Mocanu, M., Carr, R. D., Brand, C. L., & Yellon, D. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 642 · see citing works
Bergenstal, R. M., Wysham, C., MacConell, L., Malloy, J. L., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 607 · see citing works
Pratley, R. E., Nauck, M. A., Bailey, T. S., Montanya, E., Cuddihy, R. M., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 582 · see citing works
Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565 · see citing works
Initiating Insulin Therapy in Type 2 Diabetes
Raskin, P., Allen, E., Hollander, P., Lewin, A., Gabbay, R. A., Hu, P., Bode, B., Garber, A., & for the INITIATE Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.2.260 · Cited by 560 · see citing works
Kolterman, O., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D. S., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 549 · see citing works
Rosenstock, J., Brazg, R., Andryuk, P. J., Lu, K., & Stein, P. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.007 · Cited by 514 · see citing works
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · see citing works
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502 · see citing works
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486 · see citing works
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468 · see citing works
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J. P., Verhoeven, R., Bugáňová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 467 · see citing works
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465 · see citing works
Nielsen, L. L., Young, A. A., & Parkes, D. G. (2003) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 455 · see citing works
Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448 · see citing works
Kim, D. S., MacConell, L., Zhuang, D., Kothare, P. A., TRAUTMANN, M. E., Fineman, M. S., & Taylor, K. (2007) · Diabetes Care · doi:10.2337/dc06-2375 · Cited by 447 · see citing works
Vilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444 · see citing works
Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442 · see citing works
Heusch, G., Boengler, K., & Schulz, R. (2008) · Circulation · doi:10.1161/circulationaha.108.805242 · Cited by 435 · see citing works
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes
Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. (2009) · Diabetes Care · doi:10.2337/dc08-1755 · Cited by 434 · see citing works
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434 · see citing works
Kolterman, O., Kim, D. D. H., Shen, L. Z., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434 · see citing works
Nauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R. G., & TRAUTMANN, M. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 430 · see citing works
The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes
Zinman, B., Hoogwerf, B. J., García, S. D., Milton, D. R., Giaconia, J. M., Kim, D. D. H., TRAUTMANN, M. E., & Brodows, R. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-7-200704030-00003 · Cited by 422 · see citing works
Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00602.x · Cited by 416 · see citing works
Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396 · see citing works
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388 · see citing works
Umpierrez, G., Tofé Povedano, S., Pérez Manghi, F., Shurzinske, L., & Pechtner, V. (2014) · Diabetes Care · doi:10.2337/dc13-2759 · Cited by 341 · see citing works
Russell-Jones, D. L., Cuddihy, R. M., Hanefeld, M., Kumar, A., González‐González, J. G., Chan, M., Wolka, A. M., Boardman, M. K., & on behalf of the DURATION-4 Study Group (2011) · Diabetes Care · doi:10.2337/dc11-1107 · Cited by 334 · see citing works
Pratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70214-6 · Cited by 326 · see citing works
Dore, D. D., Seeger, J. D., & Chan, K. A. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 324 · see citing works
Salehi, M., Prigeon, R. L., & D’Alessio, D. A. (2011) · Diabetes · doi:10.2337/db11-0203 · Cited by 323 · see citing works
Li, Y., Duffy, K. B., Ottinger, M. A., Ray, B., Bailey, J. A., Holloway, H. W., Tweedie, D., Perry, T., Mattson, M. P., Kapogiannis, D., et al. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1314 · Cited by 319 · see citing works
Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats
Szayna, M., Doyle, M. E., Betkey, J. A., Holloway, H. W., Spencer, R. G. S., Greig, N. H., & Egan, J. M. (2000) · Endocrinology · doi:10.1210/endo.141.6.7490 · Cited by 303 · see citing works
Nauck, M. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 293 · see citing works
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
Yu, M., Moreno, C., Hoagland, K. M., Dahly, A., Ditter, K., Mistry, M., & Roman, R. (2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00012 · Cited by 292 · see citing works
Zinman, B., Gerich, J. E., Buse, J. B., Lewin, A., Schwartz, S. E., Raskin, P., Hale, P. M., Zdravkovic, M. D., & Blonde, L. (2010) · Diabetes Care · Cited by 290 · see citing works
Balani, A. R., & Grendell, J. H. (2008) · Drug Safety · doi:10.2165/00002018-200831100-00002 · Cited by 286 · see citing works
Inhibition of mitochondrial permeability transition pore opening: the holy grail of cardioprotection
Heusch, G., Boengler, K., & Schulz, R. (2010) · Basic Research in Cardiology · doi:10.1007/s00395-009-0080-9 · Cited by 281 · see citing works
Elbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279 · see citing works
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261 · see citing works
Seino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255 · see citing works
DeYoung, M. B., MacConell, L., Sarin, V., TRAUTMANN, M. E., & Herbert, P. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0050 · Cited by 242 · see citing works
Incretin-Based Therapies in Type 2 Diabetes Mellitus
Chia, C. W., & Egan, J. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2109 · Cited by 221 · see citing works
Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213 · see citing works
Rosenstock, J., Fonseca, V. A., Gross, J. L., Ratner, R. E., Åhrén, B., Chow, F. C. C., Yang, F., Miller, D. M., JOHNSON, S. L., Stewart, M. W., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0001 · Cited by 212 · see citing works
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
Mannucci, E., Pala, L., Ciani, S., Bardini, G., Pezzatini, A., Sposato, I., Cremasco, F., Ognibene, A., & Rotella, C. M. (2005) · Diabetologia · doi:10.1007/s00125-005-1749-8 · Cited by 206 · see citing works
Self-citationKapitza, C., Forst, T. M., Coester, H. V., Poitiers, F., Ruus, P., & Hincelin-Méry, A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12076 · Cited by 192 · see citing works
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism
Nyström, T., Gonon, A. T., Sjöholm, Å., & Pernow, J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.024 · Cited by 188 · see citing works
Buse, J. B., Sesti, G., Schmidt, W. E., Montanya, E., Chang, C., Xu, Y., Blonde, L., Rosenstock, J., & for the Liraglutide Effect Action in Diabetes (LEAD)-6 Study Group (2010) · Diabetes Care · doi:10.2337/dc09-2260 · Cited by 177 · see citing works
Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12175 · Cited by 174 · see citing works
Self-citationUlrich, W., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 173 · see citing works
Arnolds, S., Dellweg, S., Clair, J., Dain, M., Nauck, M. A., Rave, K., & Kapitza, C. (2010) · Diabetes Care · doi:10.2337/dc09-2191 · Cited by 167 · see citing works
Ratner, R. E., Rosenstock, J., Boka, G., & on behalf of the DRI6012 Study Investigators (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03020.x · Cited by 155 · see citing works
Waget, A., Cabou, C., Masseboeuf, M., Cattan, P., Armanet, M., Karaca, M., Castel, J., Garret, C., Payros, G., Maida, A., et al. (2011) · Endocrinology · doi:10.1210/en.2011-0286 · Cited by 153 · see citing works
Thrainsdottir, I. S., Malmberg, K., Olsson, A., Gutniak, M., & Rydén, L. (2004) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2004.005 · Cited by 121 · see citing works
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors
Pratley, R. E., & Gilbert, M. P. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.73 · Cited by 111 · see citing works
Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.010 · Cited by 106 · see citing works
Self-citationMannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Fanelli, A., Messeri, G., & Rotella, C. M. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00367.x · Cited by 106 · see citing works
Self-citationLiraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus
Vilsbøll, T. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.231 · Cited by 95 · see citing works
Lixisenatide for type 2 diabetes mellitus
Christensen, M., Knop, F. K., Vilsbøll, T., & Holst, J. J. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.562191 · Cited by 84 · see citing works
Lønborg, J., Vejlstrup, N. G., Kelbæk, H., Nepper‐Christensen, L., Jørgensen, E. O., Helqvist, S., Holmvang, L., Saunamäki, K. I., Bøtker, H. E., Kim, W. Y., et al. (2014) · Diabetes · doi:10.2337/db13-1849 · Cited by 83 · see citing works
Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells
Pala, L., Mannucci, E., Pezzatini, A., Ciani, S., Sardi, J., Raimondi, L., Ognibene, A., Cappadona, A., Vannelli, B., & Rotella, C. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.111 · Cited by 76 · see citing works
Self-citationGARCIADORADO, D., Rodríguez‐Sinovas, A., Ruiz‐Meana, M., Inserte, J., Agulló, L., & Cabestrero, A. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.02.011 · Cited by 69 · see citing works
Scott, D. A., Boye, K. S., Timlin, L., Clark, J. F., & Best, J. H. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12007 · Cited by 65 · see citing works
A synthetic glucagon-like peptide-1 analog with improved plasma stability
Ritzel, U., Leonhardt, U., Ottleben, M., Rühmann, A., Eckart, K., Spiess, J., & Ramadori, G. P. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1590093 · Cited by 61 · see citing works
Trujillo, J. M., & Nuffer, W. A. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014545807 · Cited by 59 · see citing works
Home, P. (2007) · Diabetologia · doi:10.1007/s00125-007-0653-9 · Cited by 58 · see citing works
Ha, S. J., Kim, W., Woo, J. S., Kim, J., Kim, S., Kim, W.-S., Kim, M. K., Cheng, X. W., & Kim, K. S. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.222653 · Cited by 58 · see citing works
Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors
Stonehouse, A. H., Okerson, T. E., Kendall, D. M., & Maggs, D. G. (2008) · Current Diabetes Reviews · doi:10.2174/157339908784220705 · Cited by 54 · see citing works
Watson, E., Jonker, D. M., Jacobsen, L. V., & Ingwersen, S. H. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009354996 · Cited by 53 · see citing works
Lindamood, C., & Taylor, J. R. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.01.003 · Cited by 20 · see citing works
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12 · see citing works
IDRIS, I. R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00834.x · Cited by 6 · see citing works
Flagged first, then by citations
2 of the 109 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Gilbert, M. P., & Pratley, R. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00178 · Cited by 407 · see citing works
Rosenstock, J., Aronson, R., Grunberger, G., Hanefeld, M., Piatti, P., Sérusclat, P., Cheng, X., Zhou, T., Niemoeller, E., Souhami, E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0917 · Cited by 273 · see citing works
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248 · see citing works
Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13120 · Cited by 245 · see citing works
Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240 · see citing works
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171 · see citing works
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 161 · see citing works
The FLAT-SUGAR Trial Investigators (2016) · Diabetes Care · doi:10.2337/dc15-2782 · Cited by 135 · see citing works
GLP-1 receptor agonists and cardiovascular outcome trials: An update
Andrikou, E., Tsioufis, C. P., Andrikou, I., Leontsinis, I., Tousoulis, D. M., & Παπάνας, Ν. (2018) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2018.11.008 · Cited by 114 · see citing works
Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Alavi, S. E., Cabot, P. J., & Moyle, P. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00308 · Cited by 99 · see citing works
Thangavelu, T., Lyden, E., & Shivaswamy, V. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00786-1 · Cited by 96 · see citing works
GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials
Kapoor, I., Sarvepalli, S. M., D’Alessio, D. A., Grewal, D. S., & Hadziahmetovic, M. (2023) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2023.07.002 · Cited by 86 · see citing works
Batista, A. F., Bodart‐Santos, V., Felice, F. G. D., & Ferreira, S. T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0593-6 · Cited by 77 · see citing works
The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients
Kukla, A., Hill, J., Merzkani, M., Bentall, A., Lorenz, E. C., Park, W. D., D’Costa, M., Kudva, Y. C., Stegall, M. D., & Shah, P. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000000971 · Cited by 73 · see citing works
Zhang, L., Tian, J., Diao, S., Zhang, G., Xiao, M., & Chang, D. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109252 · Cited by 73 · see citing works
Oseguera‐Toledo, M. E., de Mejı́a, E. G., Sivaguru, M., & Amaya‐Llano, S. L. (2016) · Journal of Functional Foods · doi:10.1016/j.jff.2016.09.001 · Cited by 70 · see citing works
Mannucci, E., Dicembrini, I., Nreu, B., & Monami, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13888 · Cited by 62 · see citing works
Self-citationLavan, R. P., Tunceli, K., Zhang, D., Normile, D. M., & Armstrong, R. (2017) · Parasites & Vectors · doi:10.1186/s13071-017-2217-2 · Cited by 60 · see citing works
Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms
Kato, S., Sato, T., Fujita, H., Kawatani, M., & Yamada, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-88612-x · Cited by 59 · see citing works
Vanhove, T., Remijsen, Q., Kuypers, D. R. J., & Gillard, P. (2016) · Transplantation Reviews · doi:10.1016/j.trre.2016.09.001 · Cited by 54 · see citing works
Owens, D. R., Monnier, L., & Barnett, A. H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12977 · Cited by 52 · see citing works
Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence
Herman, R. J., & Schmidt, H. D. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114565 · Cited by 53 · see citing works
Evers, A., Bossart, M., Pfeiffer‐Marek, S., Elvert, R., Schreuder, H., Kurz, M. E., Stengelin, S., Lorenz, M., Herling, A. W., Konkar, A. A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00292 · Cited by 50 · see citing works
The Role of Glucagon-Like Peptide-1 in Energy Homeostasis
Salehi, M., & Purnell, J. Q. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0088 · Cited by 49 · see citing works
Monami, M., Zannoni, S., Pala, L., Silverii, G. A., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.163 · Cited by 45 · see citing works
Self-citationAn update on pharmacotherapies in diabetic dyslipidemia
Gupta, M., Tummala, R., Ghosh, R. K., Blumenthal, C., Philip, K., Bandyopadhyay, D., Ventura, H. O., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.006 · Cited by 43 · see citing works
GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
Jia, X., Alam, M., Ye, Y., Bajaj, M., & Birnbaum, Y. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6773-2 · Cited by 37 · see citing works
Mills, E. P., Brown, K. P. D., Smith, J. D., Vang, P. W., & Trotta, K. (2017) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817741852 · Cited by 37 · see citing works
Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice
Arora, T., Wegmann, U., Bobhate, A., Lee, Y. S., Greiner, T. U., Drucker, D. J., Narbad, A., & Bäckhed, F. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.006 · Cited by 35 · see citing works
Lin, J., Lingohr-Smith, M., & Fan, T. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s117200 · Cited by 31 · see citing works
Novel application of hydrophobin in medical science: a drug carrier for improving serum stability
Zhao, L., Xu, H., Li, Y., Song, D., Wang, X., Qiao, M., & Gong, M. (2016) · Scientific Reports · doi:10.1038/srep26461 · Cited by 30 · see citing works
Li, C., Yang, M., Wang, X., Zhang, H., Yao, C., Sun, S., Liu, Q., Pan, H., Liu, S., Huan, Y., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.029 · Cited by 29 · see citing works
Kuthati, Y., Davuluri, V. N. G., & Wong, C. (2025) · Biomolecules · doi:10.3390/biom15050622 · Cited by 29 · see citing works
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment
Chodorge, M., Celeste, A. J., Grimsby, J. S., Konkar, A. A., Davidsson, P., Fairman, D., Jenkinson, L., Naylor, J., White, N., Seaman, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35869-4 · Cited by 25 · see citing works
Dog owner flea/tick medication purchases in the USA
Lavan, R. P., Armstrong, R., Tunceli, K., & Normile, D. M. (2018) · Parasites & Vectors · doi:10.1186/s13071-018-3142-8 · Cited by 24 · see citing works
Liu, Q., Garg, P., Hasdemir, B., Wang, L., Tuscano, E., Sever, E. N., Rivera, E. K., Hernandez, A. G. L., Yuan, T. Z., Kwan, E., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1893425 · Cited by 23 · see citing works
Wysham, C., Campos, C., & Kruger, D. F. (2018) · Clinical Diabetes · doi:10.2337/cd17-0064 · Cited by 23 · see citing works
Syed, O., Jancic, P., & Knežević, N. N. (2023) · Pharmaceuticals · doi:10.3390/ph16060801 · Cited by 24 · see citing works
Li, F.-F., Jiang, L., Fu, L., Zhu, H., Zhou, P., Zhang, D., Su, X., Wu, J.-D., Ye, L., & Ma, J. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0222-7 · Cited by 22 · see citing works
Taricska, N., Horváth, D., Menyhárd, D. K., Ákontz‐Kiss, H., Noji, M., So, M., Goto, Y., Fujiwara, T., & Perczel, A. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201903826 · Cited by 21 · see citing works
Hunt, B., Ye, Q., Valentine, W. J., & Ashley, D. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0219-2 · Cited by 20 · see citing works
Lisco, G., Tullio, A. D., Disoteo, O., Geronimo, V. D., Piazzolla, G., Pergola, G. D., Giagulli, V. A., Jirillo, E., Guastamacchia, E., Sabbà, C., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.920541 · Cited by 21 · see citing works
Watkins, A. R., Fialka, N. M., EL‐Andari, R., Kang, J. J. H., Bozso, S. J., & Nagendran, J. (2023) · Future Cardiology · doi:10.2217/fca-2022-0093 · Cited by 19 · see citing works
Conlon, J. M., Moffett, R. C., Leprince, J., & Flatt, P. R. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7537-2_21 · Cited by 18 · see citing works
Vedtofte, L., Knop, F. K., & Vilsbøll, T. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1288715 · Cited by 17 · see citing works
Tsai, S., & Chen, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133152 · Cited by 16 · see citing works
Bellanca, C. M., Augello, E., Benedetto, G. D., Burgaletto, C., Cantone, A. F., Cantarella, G., Bernardini, R., Polosa, R., & the DiaSmokeFree Working Group (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1406860 · Cited by 16 · see citing works
Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys
Cui, Q., Liao, Y., Jiang, Y., Huang, X., Tao, W., Zhou, Q., Shao, A., Zhao, Y., Li, J., Ma, A., et al. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0255 · Cited by 15 · see citing works
Duration of annual canine flea and tick protection provided by dog owners in Spain
Lavan, R. P., Armstrong, R., Burgio, F., & Tunceli, K. (2018) · Parasites & Vectors · doi:10.1186/s13071-018-3043-x · Cited by 15 · see citing works
Drug discovery approaches targeting the incretin pathway
Deng, X., Tavallaie, M. S., Sun, R., Wang, J., Cai, Q., Shen, J., Lei, S., Fu, L., & Jiang, F. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103810 · Cited by 15 · see citing works
Engineering of smart nanoconstructs for delivery of glucagon-like peptide-1 analogs
Eissa, N. G., Elsabahy, M., & Allam, A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120317 · Cited by 16 · see citing works
Handelsman, Y., Wyne, K. L., Cannon, A. J., Shannon, M. H., & Schneider, D. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s14 · Cited by 14 · see citing works
A Data Mining Approach on Polypharmacy and Drug-drug Interactions of Common Diabetes Medications
Dwivedi, J., Kaushal, S., Wal, P., Chandrashekhar, D. J., Sharma, A., Nathiya, D., & Gasmi, A. (2025) · Current Drug Metabolism · doi:10.2174/0113892002358291250401190533 · Cited by 12 · see citing works
Davies, M. L., Pham, D. Q., & Drab, S. R. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1792 · Cited by 12 · see citing works
Glucagon-like peptide-1 receptor agonists in neoplastic diseases
Ji, L., He, X., Min, X., Yang, H., Wu, W., Xu, H., Chen, J., & Mei, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1465881 · Cited by 10 · see citing works
Xiao, M., Lu, D., Tian, J., Yu, Y., Zhang, Q., Zhang, L., & Chang, D. (2020) · RSC Advances · doi:10.1039/c9ra09959j · Cited by 10 · see citing works
Optimizing management of glycaemia
Chatterjee, S., Khunti, K., & Davies, M. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.002 · Cited by 11 · see citing works
Prato, S. D., Frías, J. P., Blonde, L., Aroda, V. R., Shehadeh, N., Saremi, A., DEX, T. A., Niemoeller, E., Souhami, E., Liu, M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14068 · Cited by 10 · see citing works
Gautier, T., Umpierrez, G. E., Renard, É., & Kovatchev, B. P. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819891170 · Cited by 9 · see citing works
NUEVOS FÁRMACOS EN DIABETES MELLITUS
Aylwin, C. G. (2016) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2016.04.013 · Cited by 9 · see citing works
Gholami, M., Balajam, N. Z., Rakhsha, S. S., Sajjadi‐Jazi, S. M., Shafiee, G., & Heshmat, R. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01604-w · Cited by 9 · see citing works
Rasalam, R. R., Barlow, J., Kennedy, M., Phillips, P., & Wright, A. F. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0642-2 · Cited by 8 · see citing works
Sha, Y., Shi, Y., Niu, B., & Chen, Q. (2017) · RSC Advances · doi:10.1039/c7ra09470a · Cited by 7 · see citing works
Li, C., Hou, S., Liu, S., Huan, Y., Sun, S., Liu, Q., & Shen, Z. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0143-8 · Cited by 7 · see citing works
Dey, A. K., Groenendyk, J., Mehta, N. N., & Gourgari, E. (2019) · Clinical Cardiology · doi:10.1002/clc.23152 · Cited by 5 · see citing works
Tudurachi, B.-S., Anghel, L., Tudurachi, A., Sascău, R. A., Zanfirescu, R.-L., & Stătescu, C. (2024) · Biomedicines · doi:10.3390/biomedicines12061314 · Cited by 6 · see citing works
Xu, L., Chen, G., Zhang, L., He, A., & Li, Y. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23618 · Cited by 6 · see citing works
Yami, M. S. A., Alfayez, O. M., & Alsheikh, R. (2018) · Heart Lung and Circulation · doi:10.1016/j.hlc.2018.03.018 · Cited by 6 · see citing works
Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
Raccah, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1268598 · Cited by 24 · see citing works
Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus
Chatterjee, R., Galave, V. S. B., & Jindal, A. B. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01965-y · Cited by 6 · see citing works
Lee, Y.-M., Lee, S., Kim, T. H., Park, E.-J., Park, Y.-A., & Jang, J. (2020) · Cardiology Journal · doi:10.5603/cj.a2020.0140 · Cited by 7 · see citing works
Cirnigliaro, C. M., Fountaine, M. F. L., Sauer, S. J., Cross, G. T., Kirshblum, S., & Bauman, W. A. (2023) · Journal of Spinal Cord Medicine · doi:10.1080/10790268.2023.2207064 · Cited by 6 · see citing works
Pharmaceutical Interventions for Diabetes Prevention in Patients at Risk
Chatterjee, S., Davies, M. J., & Khunti, K. K. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0239-y · Cited by 5 · see citing works
GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients
Montoya, P. A., Evelyn, B., Folino, C., & Allo, Y. J. M. (2020) · Current Hypertension Reviews · doi:10.2174/1573402116999201124123549 · Cited by 4 · see citing works
Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People
Sood, A., & Swislocki, A. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0134 · Cited by 4 · see citing works
Vujosevic, S., Toma, C., Ferrulli, A., Cillà, S. D., Nucci, P., & Luzi, L. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02552-w · Cited by 3 · see citing works
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3 · see citing works
Du, F., Ospina, N. S., Chen, Y., Brito, J. P., Liu, Q., Schmidt, S., McCoy, R. G., Cicali, B., Shao, H., & Jiao, T. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02971-7 · Cited by 3 · see citing works
The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients
Fadah, K., Alashi, A., & Deoker, A. (2022) · Current Cardiology Reports · doi:10.1007/s11886-021-01619-8 · Cited by 3 · see citing works
Krentz, A. J., & Rodriguez‐Araujo, G. (2017) · Pharmaceutical Medicine · doi:10.1007/s40290-017-0209-3 · Cited by 3 · see citing works
González-Gálvez, G., Díaz-Toscano, M. L., Llamas-Moreno, J. F., Fernández-Rodarte, K., & Sañudo‐Maury, M. E. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.05.020 · Cited by 3 · see citing works
Rabbani, S. A., Saini, M., El-Tanani, M. E.-T., Kumar, R., Matalka, I. I., El‐Tanani, Y., Sharma, S., & Rizzo, M. (2026) · Pharmaceuticals · doi:10.3390/ph19050732 · Cited by 3 · see citing works
Braha, A., Timar, B., Sturza, A., & Timar, R. Z. (2026) · Medicina · doi:10.3390/medicina62081509 · Cited by 2 · see citing works
Shilpa, K., & Arvind, M. N. (2016) · Journal of the Association of Physicians of India · Cited by 2 · see citing works
Kang, D., & Choi, D. (2026) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2025.277 · Cited by 1 · see citing works
“This classification is closely linked to dosing frequency and differences in the degree of delayed gastric emptying [9].”
A novel GLP-1and FGF21 fusion protein for the treatment of non-alcoholic steatohepatitis (NASH)
Zhang, Z., Ma, Y., Xie, C., He, Y., Wang, D., Song, H., Yuan, M., & Zhang, X. (2024) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.43672 · Cited by 1 · see citing works
Gu, W., Wu, X., Zhang, M., Wang, X., Du, Q., Kang, L., Lauand, F., Alvarez, A., & Mu, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70181 · Cited by 1 · see citing works
Lista, S., Ballerio, M., López‐Ortiz, S., Khoramipour, K., Imbimbo, B. P., Santos‐Lozano, A., Minoretti, P., & Emanuele, E. (2026) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2026.174217 · Cited by 1 · see citing works
Haluzı́k, M., Adamíková, A., Běhunčík, M., Macko, M., & Štěpánová, R. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.053 · Cited by 1 · see citing works
A mini review on glucagon-like peptide-1 receptor agonists and its role in blood pressure regulationPreprint
Alharbi, N. H. J. (2024) · Preprints.org · doi:10.20944/preprints202402.0005.v1
Blundell, J. E., Axelsen, M. B., Brooks, A., Flint, A., Kvist, T., Bergan, E. Q., & Hjerpsted, J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(16)31220-7
How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies
Inzucchi, S. E., & Matthews, D. R. (2016) · doi:10.1002/9781118924853.ch33
The entero-insular axis and metabolic syndrome
Sarkar, J., & Chakrabarti, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00047-5
Initiating non-insulin-based treatment in adults with type 2 diabetes: a practical guide
Stewart, M. (2024) · Primary Health Care · doi:10.7748/phc.2024.e1828
Modern Methods of Pharmacological Correction of Diabetic Polyneuropathy
Tsepelev, V. Y., Masaleva, I. O., Владимировна, Б. Н., Polyakova, O. V., & Викторович, Г. С. (2025) · Ural Medical Journal · doi:10.52420/umj.24.1.142
Chuang, S., Liu, S.-C., Chien, K., Lin, C. Y., Tsai, M.-C., & Shih, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70915
Yin, M., Guo, S., Gu, J., Zhang, Y. H., Yang, L., Zhang, Y. H., Zhang, X., Chang, X., Feng, S., Naiel, M. A. E., et al. (2026) · Journal of Fish Biology · doi:10.1111/jfb.70549
Kurowski, M., Rekiel, K., Marcinkowska, A., Ratajczyk, O., Urbanowicz, P., Iwankiewicz, S., Grzelczak, W., & mierczak, Z. K. (2026) · Medical Journal of Cell Biology · doi:10.2478/acb-2026-0005
- Authors
- Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A.
- Affiliations
- University of Milan (IT)
- MultiMedica (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Hospital Clínic de Barcelona (ES)
- Corresponding author
- Uccellatore, Annachiara
- Venue
- Diabetes Therapy
- Published
- 2015-08-14
- Volume
- 6
- Issue
- 3
- Pages
- 239-256
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC4575308
- OpenAlex
- W1695457816
- Cited by
- 99
- References
- 109
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 8 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 11 · 2019: 11 · 2018: 13 · 2017: 11 · 2016: 18
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, exenatide, exenatide twice daily, exenatide once weekly, liraglutide, lixisenatide, dulaglutide, albiglutide, metformin add-on therapy, drug selection, duration of action, hypoglycemia risk, weight gain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
